Press Releases
This document provides integrated information to the media. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
-
LicensingItalfarmaco and JCR Pharmaceuticals Enter into Exclusive License Agreement for the Development and Potential Commercialization of Novel Investigational Therapy for Hunter Syndrome in the United States, Europe, and Latin AmericaView PDF
-
CorporateNotice of Organizational and Personnel ChangesView PDF
-
R&DJCR Pharmaceuticals Receives Orphan Drug Designation from the Ministry of Health, Labour and Welfare of Japan for Givinostat for Duchenne Muscular DystrophyView PDF
-
CorporateNotice Regarding the Resignation of an Outside DirectorView PDF
-
R&DMEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Dose First Patient in Global Phase I/II Trial of JR-446 for Mucopolysaccharidosis Type IIIBView PDF
-
SustainabilityJCR Pharmaceuticals Joins “Relay For Life of Ashiya” in Support of the Cancer CommunityView PDF
-
SustainabilitySupport for People and Communities Affected by the 2026 Kumamoto Prefecture EarthquakeView PDF
-
FinancesFY2026 First Quarter Results Briefing Session - Script
-
FinancesFY2026 First Quarter Results Briefing Session - Material
-
FinancesFY2026-Q1 Financial Report (Apr. 1-Jun. 30, 2026)